Tesamorelin clinical trials showed continued improvement out to 26 weeks, suggesting that longer protocols produce greater cumulative benefit
These results were in accordance with other results published previously by the present groups, where the AEDG peptide and the mixture of AEDG, KED, KED and AED peptides increased expression GAP43 and Nestin genes and proteins in hPDLSCs [27]
* Correspondence: Dagmara Lisman, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
PeruzzoloTLPintoJVRozaTHShintaniAOAnzolinAPGnielkaVet al
Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z et al
doi: 10.1124/jpet.300.3.762